BioWorld

Nov. 14, 2007

Ambit's Series D Raises $50M For Kinase Inhibitor Program

With one kinase inhibitor in the clinic and two more in the queue, Ambit Biosciences Corp. raised $49.3 million in a Series D financing round. (BioWorld Today) Read More

Competition For Few Compounds Drives Up Deal Costs, Complexity

Acambis Partners West Nile Vaccine In $80M Sanofi Deal

Smoke Clears; Pfizer Paying Nektar $135M In Exubera Deal

AVAX Starts Pivotal Testing With M-Vax Cancer Vaccine

VaxGen, Raven Get 'Fresh Start' Via Merger To Focus On Cancer

Other News To Note

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for Jan 9, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Jan. 9, 2026.

3D rendering of antibody drug conjugated with cytotoxic payload

ADCs’ breakout 2025 and their still-unfinished potential

BioWorld Science

Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...

Development and characterization of anti-CD19 in vivo CAR T therapy

BioWorld Science

Shenzhen Grit Biotechnology Co. Ltd. and Shanghai Vitalgen Biopharma Co. Ltd. recently presented their work to develop and evaluate a novel anti-CD19 in vivo CAR...

Preclinical results of anti-ADAMTS13 antibody in acquired von Willebrand syndrome

BioWorld Science

The acquired von Willebrand syndrome (AVWS) is a rare bleeding disorder with laboratory findings similar to those of inherited von Willebrand disease. Researchers...